This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NxStage Extends Agreement To Supply Streamline Bloodlines, MasterGuard And Buttonhole Needle Technology To B. Braun

Stocks in this article: NXTM

LAWRENCE, Mass., Jan. 9, 2012 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems in-center business and B. Braun Medical Inc. have agreed to extend their supply agreement under which Medisystems will supply B. Braun with its Streamline ® blood tubing sets for use on the B. Braun Dialog ® and Dialog hemodialysis systems, Medisystems MasterGuard ® and Buttonhole ® needles, and ancillary products for sale in the U.S. Under the terms of the amended agreement, which has been extended through 2014, B. Braun will provide sales, marketing and clinical support to its customers in the U.S.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

"Medisystems' Streamline technology has fast become our standard bloodline product, with our customers reporting improved operational efficiencies," said Sam Amory, Vice President B. Braun Renal Therapies Division. "We are pleased to provide Streamline as well as Medisystems MasterGuard and Buttonhole needles and ancillary products so our customers can provide excellent dialysis care."

Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes NxStage's patented LockSite ® needleless access ports, which eliminates the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.

"This agreement validates the excellent performance of Medisystems' Streamline blood tubing sets and demonstrates our continued commitment to provide B. Braun customers with market leading products," said Mark Florence, Vice President and General Manager, Medisystems. "We look forward to working with B. Braun to meet the growing demand for Streamline."

About B. Braun Renal Therapies Division

B. Braun has been a leader in providing the dialysis community with innovative products for over 35 years.  The Dialog hemodialysis system incorporates the most advanced state-of-the art technology in dialysis.  As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone ® dialyzers, the Renal Therapies Division of B. Braun is committed to the continued development of high quality products for hemodialysis and continuous renal replacement therapy supported by a team of clinical nurses, field service personnel, customer service and 24/7 technical assistance.   For more information, call 800-848-2066, e-mail B. Braun at rtd.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts:

Kristen Sheppard, Esq.Vice President, Investor RelationsNxStage Medical, Inc. ir@nxstage.com978-332-5923

SOURCE NxStage Medical, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs